Sodium oxybate (SO) is a γ-amino-butyric acid (GABA)-ergic drug currently used for the treatment of alcohol dependence (AD) in some European countries. The aim of this study was to describe the effect of SO administration in alcoholics classified according to Lesch alcoholism typology (LAT). Forty-eight patients were enrolled and classified into four groups according to LAT. All patients were treated with oral SO (50 mg/kg of body weight t.i.d.) for 12 weeks. All patients significantly reduced their alcohol intake (p<0.001). Alcohol abstinence during the 12 weeks of treatment did not differ between the four groups at the end of treatment. Craving for SO did not significantly differ amongst groups; cases of SO abuse were very limited and were observed in almost 10% of patients. In conclusion, our study showed an overall efficacy of SO in the treatment of AD irrespective of LAT categories. However, our results confirm that alcoholics with psychiatric co-morbidity, particularly with a borderline personality disorder of Axis II, are at a greater risk of developing craving for and abuse of the drug: until craving for alcohol and craving for SO are characterized in depth, SO should be used with caution in these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0269881113504015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium Oxybate-Treated Familial Myoclonus-Dystonia Syndrome Due to Novel SGCE Variant.
Am J Med Genet A
December 2024
Medical Genetic Division, Department of Pediatrics, King Saud University Medical City, Riyadh, Saudi Arabia.
Myoclonus-dystonia syndrome (MDS, OMIM #159900) is an autosomal-dominant movement disorder caused by heterozygous variants in the epsilon sarcoglycan gene (SGCE) and characterized by a combination of myoclonic jerks, dystonia, and psychiatric comorbidities. Patients with MDS have a normal life expectancy with markedly reduced quality of life. Here, we report four family members diagnosed with MDS of variable severity due to a novel heterozygous splicing variant in SGCE (c.
View Article and Find Full Text PDFEfficacy of sodium oxybate plus disulfiram for the maintenance of alcohol abstinence in treatment-resistant patients with alcohol use disorder: a multicentre retrospective study.
Ann Ist Super Sanita
December 2024
Dipartimento di Medicina Traslazionale e per la Romagna, Università di Ferrara, Ferrara, Italy.
Introduction: Disulfiram (DF), acamprosate, naltrexone, baclofen and sodium oxybate (SO) are currently the medications approved for the treatment of alcohol use disorder (AUD). In this context, combined pharmacological interventions and sex differences are an interesting area in the treatment of non-responder AUD patients.
Aim: To evaluate the efficacy of SO in combination with DF in maintaining alcohol abstinence in patients with AUD who failed to achieve abstinence either with SO or DF alone.
Initial evaluation of 4-palmitoyloxy butyrate in whole blood as potential biomarker after γ-hydroxybutyric acid intake.
J Anal Toxicol
December 2024
Institute of Forensic Medicine, Forensic Toxicology, University of Bonn, Stiftsplatz 12, 53111 Bonn, Germany.
The problem of finding a suitable biomarker to widen the detection window of γ-hydroxybutyric acid (GHB) intake remains a challenge in forensic toxicology. Based on previously published results, the present study deals with the evaluation of a fatty acid ester of GHB (4-palmitoyloxy butyrate (GHB-Pal)) in whole blood as a potential biomarker to extend the detection window of GHB use e.g.
View Article and Find Full Text PDFTrends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022.
J Sleep Res
December 2024
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Clinicians and people with narcolepsy report varied access to higher-cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends for higher-cost narcolepsy drugs using new national databases.
View Article and Find Full Text PDFEfficacy and safety of sodium oxybate treatment in adults with narcolepsy and cataplexy: a systematic review and meta-analysis.
Sleep Breath
November 2024
Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Article Synopsis
- Narcolepsy is a chronic condition marked by excessive daytime sleepiness and cataplexy, and sodium oxybate (SXB) has been identified as the only effective treatment for its symptoms.
- The study reviewed five randomized controlled trials (RCTs) to evaluate the effectiveness of SXB in reducing cataplexy attacks and improving wakefulness while also considering its safety by monitoring adverse events.
- Results showed that SXB significantly reduced weekly cataplexy attacks and improved outcomes on various tests compared to placebo, particularly at higher doses, indicating it is an effective treatment for managing narcolepsy symptoms with a reasonably safe profile.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!